FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number: 3235-0287								
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Santel Donald J				<u>A</u>	2. Issuer Name and Ticker or Trading Symbol Aerovate Therapeutics, Inc. [AVTE] 3. Date of Earliest Transaction (Month/Day/Year)					(Che	eck all applic	able)	Person(s) to Iss 10% Ov Other (s	vner		
(Last)	(Fi	irst)	(Middle)		06	06/05/2024						below)	(5	below)	,	
C/O AEROVATE THERAPEUTICS, INC. 930 WINTER STREET, SUITE M-500				4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)					Line	Individual or Joint/Group Filing (Check Applicable ne) Form filed by One Reporting Person					
(Street)	AM M	A	02451		_		101.5	4 ()		·			Form f Persor		than One Repo	rting
(City)	(S	tate)	(Zip)		R	Chec	k this box	to indi	Transac icate that a tran defense condit	saction was m	nade pursua	nt to a contr	act, instructio n 10.	n or written pla	an that is intended	ı to
		Tab	le I - Non	-Deriv	vativ	e Sec	curities	s Ac	quired, Di	sposed o	f, or Be	neficiall	y Owned			
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)					Execution Da			on Date, Transaction Dispo		rities Acquired (A) or ed Of (D) (Instr. 3, 4 a		5. Amou Securitie Beneficia Owned F Reported	es Formally (D) (Following (I) (I	Form: Direct D) or Indirect I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code V	Amount	(A) or (D) Pric		Transact (Instr. 3 a	ion(s)		11501. 4)
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execution Date	ate,	Code (Inst				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$18.9	06/05/2024			A		12,500		(1)	06/04/2034	Common Stock	12,500	\$0	12,500	D	

Explanation of Responses:

1. The shares subject to this option will vest and become exercisable in full on the earlier of (i) June 5, 2025 or (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service through the applicable vesting date.

/s/ George A. Eldridge, Attorney-in-Fact

06/07/2024

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.